Anixa Biosciences
ANIX
13 hedge funds and large institutions have $477K invested in Anixa Biosciences in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
18% more capital invested
Capital invested by funds: $404K → $477K (+$73K)
13% less funds holding
Funds holding: 15 → 13 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$9.78K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$670 |
| 3 |
Wells Fargo
San Francisco,
California
|
+$503 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$450 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$16.7K |
| 2 |
BA
Bard Associates
Chicago,
Illinois
|
-$10.7K |
| 3 |
JCM
Jacobi Capital Management
Pittston,
Pennsylvania
|
-$4K |
| 4 |
MFW
Mosaic Family Wealth
St. Louis,
Missouri
|
-$1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$590 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BA
1
Bard Associates
Chicago,
Illinois
| $205K | -$10.7K | -3,200 | -6% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $133K | – | – | – |
|
|
DIA
3
Denver Investment Advisors
Denver,
Colorado
| $72K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $20K | +$9.78K | +2,934 | +132% |
|
|
5
Morgan Stanley
New York
| $19K | -$16.7K | -5,000 | -50% |
|
6
First Manhattan
New York
| $10K | – | – | – |
|
|
BFA
7
BlackRock Fund Advisors
San Francisco,
California
| $7K | +$670 | +201 | +14% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $3K | -$590 | -177 | -18% |
|
|
9
Wells Fargo
San Francisco,
California
| $3K | +$503 | +151 | +30% |
|
|
EWM
10
Evercore Wealth Management
New York
| $2K | – | – | – |
|
|
11
Bank of America
Charlotte,
North Carolina
| $2K | +$450 | +135 | +33% |
|
12
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1K | – | – | – |
|
|
JCM
13
Jacobi Capital Management
Pittston,
Pennsylvania
| – | -$4K | -1,320 | Closed |
|
|
MFW
14
Mosaic Family Wealth
St. Louis,
Missouri
| – | -$1K | -80 | Closed |
|
ANIX Hedge Fund Activity: Q3 2016 in Review
13 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q3 2016, worth a combined $477K — up 18% from $404K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ANIX and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was UBS Group, adding an estimated $9.78K. The largest seller was Morgan Stanley, cutting an estimated $16.7K.
- 13 institutional investors held Anixa Biosciences (ANIX) as of Q3 2016, down from 15 in Q2 2016.
- Funds reported $477K of Anixa Biosciences stock for Q3 2016, up 18% quarter-over-quarter.
- 0 funds opened new Anixa Biosciences positions in Q3 2016 and 2 closed out, a net change of -2 holders.
- The largest Anixa Biosciences buyer in Q3 2016 was UBS Group, an estimated $9.78K added.
- The largest Anixa Biosciences seller in Q3 2016 was Morgan Stanley, an estimated $16.7K sold.
Based on aggregated 13F filings for Q3 2016.